Net loss narrowed year-over-year as R&D and G&A expenses declined following the end of BARDA funding and a strategic shift to focus on lead vaccine and oncology programs. Cash runway extends into September 2026, but substantial doubt remains about ongoing viability without new capital.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.